Accéder au contenu
Merck

Tat-NR2B9c prevents excitotoxic neuronal superoxide production.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2015-02-12)
Yanting Chen, Angela M Brennan-Minnella, Sunil Sheth, Jamel El-Benna, Raymond A Swanson
RÉSUMÉ

The Tat-NR2B9c peptide has shown clinical efficacy as a neuroprotective agent in acute stroke. Tat-NR2B9c is designed to prevent nitric oxide (NO) production by preventing postsynaptic density protein 95 (PSD-95) binding to N-methyl-D-aspartate (NMDA) receptors and neuronal nitric oxide synthase; however, PSD-95 is a scaffolding protein that also couples NMDA receptors to other downstream effects. Here, using neuronal cultures, we show that Tat-NR2B9c also prevents NMDA-induced activation of neuronal NADPH oxidase, thereby blocking superoxide production. Given that both superoxide and NO are required for excitotoxic injury, the neuroprotective effect of Tat-NR2B9c may alternatively be attributable to uncoupling neuronal NADPH oxidase from NMDA receptor activation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Tat-NR2B9c trifluoroacetate, ≥95% (HPLC)